AI Financial Corp (NASDAQ: AIFC)

ALT5 Sigma Corporation operates through two distinct business segments focused on financial technology and biotechnology. The Company provides blockchain-powered technologies through its Fintech segment to enable migration to a new global financial paradigm while its Biotechnology segment is dedicated to finding treatments for chronic pain conditions and bringing to market drugs with non-addictive and non-sedative pain-relieving properties.

ALT5 Sigma Corporation generates revenue through its Fintech segment via installation or setup fees monthly maintenance fees and transaction fees ranging from 0.25% to 5% on all transactions including buy and sell orders or payment processing. The Company's Biotechnology segment does not currently generate revenue as it remains in the clinical development stage with no approved products to date.

The company operates through the following segments: Fintech and Biotechnology.

• Fintech segment provides next generation blockchain-powered technologies including ALT5 Pay a crypto-currency payment gateway enabling merchants to accept and make crypto-currency payments or integrate the platform into their operations and ALT5 Prime an electronic over-the-counter trading platform allowing registered customers to buy and sell digital assets with fiat currency options.

• Biotechnology segment is focused on identifying acquiring licensing developing partnering and commercializing novel non-opioid and non-addictive therapies for chronic pain including JAN101 for peripheral artery disease and JAN123 a formulation of low-dose naltrexone for complex regional pain syndrome.

ALT5 Sigma Corporation positions itself within the financial technology industry as a provider of institutional-grade blockchain solutions targeting banks broker dealers funds family offices proprietary trading firms liquidity providers financial information providers and merchants distinguishing itself from retail-focused platforms like Coinbase Kraken and Binance by serving business-to-business clients only.

The Company serves banks broker dealers funds family offices proprietary trading firms liquidity providers financial information providers payment processing partners and merchants through its Fintech segment while its Biotechnology segment targets patients suffering from peripheral artery disease and complex regional pain syndrome.